Headquarters: Dublin, Ireland
Year Established: 2015
Revenues: $14,571 (+15%)
Net INCOME: $14,695 (+275%)*
R&D: $2,576 (+9%)
TOP SELLING DRUGS
|Botox Therapeutics||chronic migraine, overactive bladder||$1,189||44%|
|Linzess/Constella||irritable bowel syndrome||$643||40%|
|Namenda XR||Alzheimer’s disease||$628||-17%|
|Alphagan/Combigan||glaucoma, ocular hypertension||$546||33%|
After selling off its generics business to Teva last year for roughly $40 billion, Allergan was active on the acquisition front in 2016, picking up a handful of biotechs to bolster its pipeline. In April it acquired Topokine Therapeutics, a clinical-stage biotech focused on topical medicines for fat reduction, for $85 million upfront, gaining XAF5, a topical agent in late-stage development for the treatment of steatoblepharon (undereye bags).
In September it inked a deal to buy Vitae Pharmaceutical for $639 million, strengthening its dermatology pipeline with the addition of VTP-43742, a Phase II orally active RORγt (retinoic acid receptor-related orphan receptor gamma) inhibitor for the potential treatment of psoriasis and other autoimmune disorders.
In the same month, Allergan bought Tobira Pharmaceuticals, a clinical-stage biopharma company developing therapies for non-alcoholic steatohepatitis (NASH) and other liver disease, for up to $1.7 billion if certain milestones are met. The acquisition adds Cenicriviroc (CVC) and Evogliptin, two development programs for the treatment of the multi-factorial elements of NASH, including inflammation, metabolic syndromes and fibrosis.
In November Allergan paid $125 million for Chase Pharmaceuticals Corp., another clinical-stage biotech developing treatments for neurodegenerative disorders including Alzheimer’s disease (AD). The deal expands Allergans central nervous system (CNS) pipeline with a Phase III-ready AD candidate—Chase’s lead compound, CPC-201, and certain backup compounds.
During the year Allergan entered several licensing agreements. One was with MedImmune, AstraZeneca’s global biologics R&D arm, for the global rights to MEDI2070, an anti-IL-23 monoclonal antibody currently in Phase II development for the treatment of moderate-to-severe Crohn’s disease and ulcerative colitis and other related conditions. Allergan paid $250 million upfront with potential payments of as much as $1.3 billion in milestones.
With Adamis Pharmaceuticals, Allergan entered into a licensing agreement with through its wholly owned subsidiary, Watson Laboratories, to commercialize Adamis’ Epinephrine Pre-filled Syringe (PFS) product candidate for the emergency treatment of anaphylaxis. Watson obtains commercial rights for the U.S. in exchange for an upfront fee and potential regulatory and performance based milestones totaling up to $32.5 million. Additionally, Watson will pay royalties based on future sales of the PFS in the U.S.
In emerging markets, Allergan, again through Watson Labs, inked a $106 million generic oncology deal with China’s CSPC Pharmaceutical Group relating to the product technology licensing and commercialization of an oncology drug in the global market.